Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash & Equivalents (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Cash & Equivalents for 17 consecutive years, with $184.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 108.11% to $184.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $184.3 million through Dec 2025, up 108.11% year-over-year, with the annual reading at $184.3 million for FY2025, 108.11% up from the prior year.
  • Cash & Equivalents hit $184.3 million in Q4 2025 for Ironwood Pharmaceuticals, up from $140.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $740.3 million in Q1 2023 to a low of $88.2 million in Q3 2024.
  • Historically, Cash & Equivalents has averaged $325.1 million across 5 years, with a median of $179.8 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: crashed 85.96% in 2023 and later soared 108.11% in 2025.
  • Year by year, Cash & Equivalents stood at $620.1 million in 2021, then grew by 5.82% to $656.2 million in 2022, then plummeted by 85.96% to $92.2 million in 2023, then fell by 3.9% to $88.6 million in 2024, then skyrocketed by 108.11% to $184.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for IRWD at $184.3 million in Q4 2025, $140.4 million in Q3 2025, and $92.9 million in Q2 2025.